Daiichi Sankyo
211 Mt. Airy Road
Basking Ridge
New Jersey
07920
United States
Tel: (908) 992-6400
Website: http://www.daiichisankyo.com/
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
521 articles about Daiichi Sankyo
-
Charleston Laboratories, Inc. And Daiichi Sankyo, Inc. Initiate Two Phase 3 Clinical Trials On Charleston's Lead Product, CL-108
11/20/2014
-
Daiichi Sankyo, Inc. And Ambit Biosciences Announce Results Of Tender Offer
11/11/2014
-
FDA Panel Backs Daiichi Sankyo, Inc.'s New A-Fib Drug Savaysa
10/31/2014
-
FDA Staff Recommends Limited Use Of Daiichi Sankyo, Inc.'s Blood Thinner Edoxaban
10/29/2014
-
Center For Connected Health And Daiichi Sankyo, Inc. Sign Agreement To Co-Develop A Mobile App To Support Patients With Atrial Fibrillation
10/22/2014
-
Perosphere Inc. And Daiichi Sankyo, Inc. Enter Into A Clinical Trial Collaboration Agreement For Phase 3 Studies Of PER977 To Investigate Reversal Of The Anticoagulant Activity Of The Investigational Factor Xa-Inhibitor Edoxaban
10/6/2014
-
Daiichi Sankyo, Inc. Boosts Cancer Pipeline With $410 Million Ambit Biosciences Buy
9/29/2014
-
Daiichi Sankyo, Inc. Receives Approval For Additional Indications Of LIXIANA® (Edoxaban) In Japan
9/26/2014
-
Daiichi Sankyo, Inc. Release: One Year Data From The PREFER In AF Registry Show Significant Changes In Atrial Fibrillation (AF) Management In Europe And Implementation Of Clinical Guidelines
9/2/2014
-
Daiichi Sankyo, Inc. Wagers Up To $650 Million On Charleston Laboratories, Inc.'s Pain And Opioid-Induced Nausea And Vomiting Drug
8/7/2014
-
Daiichi Sankyo, Inc. And Eli Lilly and Company: Heart Patients In England And Wales Offered More Choice Of Therapies As National Institute for Clinical Excellence (NICE) Extends Recommendations For Prasugrel
7/23/2014
-
Portola Pharmaceuticals, Inc. Enters Into Clinical Collaboration Agreement With Daiichi Sankyo, Inc. For Phase 3 Studies Of Factor Xa Inhibitor Antidote, Andexanet Alfa, And Edoxaban
7/7/2014
-
Pieris Achieves Milestone Payment In Daiichi Sankyo, Inc. Collaboration To Develop Anticalin® Therapeutics
6/23/2014
-
Sanford-Burnham Medical Research Institute And Daiichi Sankyo, Inc. Form AllianceTo Study Novel Drug Targets In Cardiovascular-Metabolic Diseases
5/21/2014
-
MRC Technology And Daiichi Sankyo, Inc. Collaborate To Identify Novel Targets For Drug Discovery
5/14/2014
-
Agendia BV Announces New Agreement With Daiichi Sankyo, Inc. To Support Oncology Drug Development
4/24/2014
-
Ken Keller Named President, U.S. Commercial, Daiichi Sankyo, Inc.
4/18/2014
-
Astellas Pharma Inc. And Daiichi Sankyo, Inc. Form Compound Library Sharing Partnership
3/20/2014
-
Provepharm Announces That Its Partner In Japan, Daiichi Sankyo, Inc. Has Filed An NDA For The Marketing Of The Methylene Blue Injection Medicinal Product In Japan, Made Out Of Proveblue® Methylene Blue Active Substance
3/19/2014
-
Daiichi Sankyo, Inc. Pledges Bold Action On Ranbaxy Laboratories Production Problems
1/31/2014